GVS advice onosilodrostat (Isturisa®) for the treatment of endogenous Cushing syndrome
The National Health Care Institute has completed its assessment whether osilodrostat (Isturisa®) can be included in the Medicine Reimbursement System (GVS). Osilodrostat (Isturisa®) is registered for the treatment of endogenous Cushing syndrome in adults. The National Health Care Institute advises the Minister to include osilodrostat on List 1A in cluster 0V04CDAO V.
Indication for which reimbursement is requested
Isturisa® is available as a film-coated tablet with 1, 5 or 10 mg osilodrostat (as osilodrostat phosphate) and is registered for the treatment of endogenous Cushing syndrome in adults.
National Health Care Institute's advice
The National Health Care Institute advises the Minister to include osilodrostat on List 1A in cluster 0V04CDAO V.